SK Biopharmaceuticals Co., Ltd. (KRX: 326030)
South Korea
· Delayed Price · Currency is KRW
103,300
-200 (-0.19%)
Nov 15, 2024, 3:30 PM KST
SK Biopharmaceuticals Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 33,796 | -32,883 | -139,431 | 64,846 | -247,414 | -71,519 | Upgrade
|
Depreciation & Amortization | 17,132 | 15,317 | 12,984 | 11,642 | 10,859 | 6,501 | Upgrade
|
Loss (Gain) From Sale of Assets | -149.91 | 21.11 | 11.28 | 3.02 | 0.29 | 2,007 | Upgrade
|
Asset Writedown & Restructuring Costs | 6,808 | 6,808 | 172.96 | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | -2,893 | -12,243 | 2,858 | -2,208 | -1,987 | - | Upgrade
|
Loss (Gain) on Equity Investments | 26,228 | 11,535 | 14,927 | 34,544 | - | - | Upgrade
|
Stock-Based Compensation | 3,816 | 3,233 | 60.66 | 416.71 | - | - | Upgrade
|
Other Operating Activities | -9,170 | -10,347 | 14,161 | -132,402 | 7,091 | -11,445 | Upgrade
|
Change in Accounts Receivable | -59,020 | -52,456 | -13,169 | -41,610 | -9,050 | -189.43 | Upgrade
|
Change in Inventory | -19,235 | -13,708 | -38,693 | -29,459 | -16,630 | -6,733 | Upgrade
|
Change in Accounts Payable | 6,656 | -20,711 | 6,965 | 607.69 | 8,961 | - | Upgrade
|
Change in Other Net Operating Assets | -10,718 | 11,232 | -20,767 | 748.38 | 37,443 | 44.38 | Upgrade
|
Operating Cash Flow | -6,749 | -94,201 | -159,920 | -92,872 | -210,726 | -81,335 | Upgrade
|
Capital Expenditures | -1,289 | -2,385 | -4,911 | -4,316 | -11,023 | -13,200 | Upgrade
|
Sale of Property, Plant & Equipment | - | - | - | 11.24 | - | 2,970 | Upgrade
|
Cash Acquisitions | 31,043 | 31,043 | - | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | 350.17 | -864.17 | -1,050 | -1,676 | -3,314 | -627.5 | Upgrade
|
Investment in Securities | 119,236 | 198,587 | -89,691 | 265,618 | -303,722 | -28,541 | Upgrade
|
Other Investing Activities | -1,593 | -1,104 | -10.78 | -639.56 | -714.24 | -68.67 | Upgrade
|
Investing Cash Flow | 147,713 | 225,273 | -95,714 | 258,971 | -318,730 | -39,465 | Upgrade
|
Short-Term Debt Issued | - | - | - | - | 150,000 | 100,000 | Upgrade
|
Long-Term Debt Issued | - | - | 141,751 | - | - | - | Upgrade
|
Total Debt Issued | 100,000 | - | 141,751 | - | 150,000 | 100,000 | Upgrade
|
Short-Term Debt Repaid | - | - | - | - | -250,000 | - | Upgrade
|
Long-Term Debt Repaid | - | -5,575 | -5,477 | -4,827 | -4,562 | -2,759 | Upgrade
|
Total Debt Repaid | -80,194 | -5,575 | -5,477 | -4,827 | -254,562 | -2,759 | Upgrade
|
Net Debt Issued (Repaid) | 19,806 | -5,575 | 136,274 | -4,827 | -104,562 | 97,241 | Upgrade
|
Issuance of Common Stock | - | - | - | - | 645,465 | - | Upgrade
|
Other Financing Activities | 12,147 | 12,198 | -1,360 | 180.69 | - | - | Upgrade
|
Financing Cash Flow | 31,953 | 6,623 | 134,914 | -4,646 | 540,902 | 97,241 | Upgrade
|
Foreign Exchange Rate Adjustments | 5,503 | -2,054 | -1,143 | 5,135 | -3,254 | 408.33 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | - | - | 0 | - | - | Upgrade
|
Net Cash Flow | 178,419 | 135,640 | -121,863 | 166,589 | 8,192 | -23,151 | Upgrade
|
Free Cash Flow | -8,038 | -96,586 | -164,831 | -97,188 | -221,749 | -94,534 | Upgrade
|
Free Cash Flow Margin | -1.73% | -27.22% | -66.96% | -23.21% | -852.91% | -76.33% | Upgrade
|
Free Cash Flow Per Share | -102.64 | -1233.33 | -2104.77 | -1241.01 | -3089.90 | -1454.38 | Upgrade
|
Cash Interest Paid | 9,297 | 8,142 | 3,488 | 844.19 | 4,441 | 1,234 | Upgrade
|
Cash Income Tax Paid | 10,475 | 8,126 | 4,681 | 6,160 | 6,389 | 707.68 | Upgrade
|
Levered Free Cash Flow | -15,349 | -54,562 | -108,210 | 51,274 | -163,014 | -57,633 | Upgrade
|
Unlevered Free Cash Flow | -9,104 | -49,387 | -105,888 | 51,865 | -160,225 | -56,666 | Upgrade
|
Change in Net Working Capital | 50,555 | 38,004 | 30,987 | 13,133 | 7,060 | -197.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.